Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Wenjie Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7753-695X; OpenAlex author ID A5100385514. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 9

  1. Corrigendum to "NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-I" [Drug … Co-author DOI 10.1016/j.drup.2025.101269↗
  2. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1. Co-author DOI 10.1016/j.drup.2023.101040↗
  3. Exosomal non-coding RNA: A new frontier in diagnosing and treating pancreatic cancer: A review. First author DOI 10.1016/j.ijbiomac.2024.130149↗
  4. Cancer-associated fibroblasts barrier breaking via TGF-β blockade paved way for docetaxel micelles delivery to treat pancreatic cancer. Co-author DOI 10.1016/j.ijpharm.2024.124706↗
  5. Intratumoral microbiota: A new force in diagnosing and treating pancreatic cancer. First author DOI 10.1016/j.canlet.2022.216031↗
  6. Small extracellular vesicles: from mediating cancer cell metastasis to therapeutic value in pancreatic cancer. Co-author DOI 10.1186/s12964-021-00806-y↗
  7. CD248(TEM1/CD164L1/Endosialin): A new molecular target for anti-angiogenic therapy in Pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-217476/v1↗
  8. Long noncoding RNA Linc00337 functions as an E2F1 co-activator and promotes cell proliferation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-020-01725-5↗
  9. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Co-author DOI 10.18632/oncotarget.2200↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daorong Wang · 4 shared papers, 2021–2024 · strength 0.76
  2. Dong Tang · 4 shared papers, 2021–2024 · strength 0.76
  3. Beicheng Sun · 2 shared papers, 2024–2025 · strength 0.52
  4. Zhiheng Zhang · 2 shared papers, 2024–2025 · strength 0.52
  5. Gengyu Sha · 2 shared papers, 2023–2024 · strength 0.48
  6. Huan Zhang · 2 shared papers, 2021–2022 · strength 0.28
  7. Zhengting Jiang · 1 shared paper, 2024 · strength 0.26
  8. Xian Qi · 1 shared paper, 2024 · strength 0.23
  9. Ning Pang · 1 shared paper, 2024 · strength 0.23
  10. Zhengting Jiang · 1 shared paper, 2023 · strength 0.22
  11. Zhilin Zhang · 1 shared paper, 2023 · strength 0.22
  12. Huakai Wang · 1 shared paper, 2020 · strength 0.11
  13. Qi Zhu · 1 shared paper, 2020 · strength 0.11
  14. Honggang Xiang · 1 shared paper, 2020 · strength 0.11
  15. Zekuan Xu · 1 shared paper, 2014 · strength 0.04
  16. Guoxin Zhang · 1 shared paper, 2014 · strength 0.04
  17. Bin Wang · 1 shared paper, 2014 · strength 0.04
  18. Zheng Chen · 1 shared paper, 2014 · strength 0.04
  19. Jin Feng · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.